Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) operates as the world leader in serving science, enabling customers to make the world healthier, cleaner and safer through an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services. The company maintains its website at… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Thermo Fisher Scientific does
In the company’s own words
Thermo Fisher Scientific Inc. (NYSE: TMO) operates as the world leader in serving science, enabling customers to make the world healthier, cleaner and safer through an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services. The company maintains its website at thermofisher.com.
The company serves a diverse customer base including pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental, industrial and quality control settings. Thermo Fisher operates through four reportable business segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services.
Life Sciences Solutions provides reagents, instruments and consumables for biological and medical research, drug discovery and vaccine production, encompassing biosciences, genetic sciences and bioproduction businesses. Analytical Instruments offers chromatography, mass spectrometry, chemical analysis and electron microscopy solutions for pharmaceutical, biotechnology, academic and industrial markets. Specialty Diagnostics delivers diagnostic test kits, reagents, culture media and instruments across clinical diagnostics, immunodiagnostics, microbiology and transplant diagnostics. Laboratory Products and Biopharma Services combines self-manufactured and sourced laboratory products with comprehensive outsourced services for pharmaceutical and biotech industries, including drug development, clinical research and commercial manufacturing.
The company operates under industry-leading brands including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. As of December 31, 2025, Thermo Fisher employed approximately 125,000 colleagues globally, distributed across the Americas with 59,000 employees, Asia-Pacific with 22,000 employees, and Europe, the Middle East and Africa with 44,000 employees. The company maintains approximately 14,000 sales personnel including highly trained technical specialists.
Thermo Fisher pursues growth through organic investments in research and development, capacity expansion and strategic acquisitions. The company recorded significant goodwill and indefinite-lived intangible assets totaling approximately 49.36 billion and 1.23 billion dollars respectively as of December 31, 2025, reflecting its acquisition-driven growth strategy. The company's competitive advantages derive from technical performance, product differentiation, service quality, active research programs and reputation as a quality provider.
Company details
- Sector
- Health Care
- Industry (SIC)
- Medical Instruments
- Headquarters
- WALTHAM, MA
- Fiscal year end
- December
- CIK
- 97745
- SIC
- 3829
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Thermo Fisher Scientific — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Thermo Fisher Scientific · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Thermo Fisher Scientific’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Thermo Fisher Scientific’s bonds, as funds hold them
Funds report holding 36 issues of Thermo Fisher Scientific’s debt, $2.39B at market value — what funds hold, not the company’s total debt. Weighted-average coupon 4.17%, maturing 2026 to 2049.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Thermo Fisher Scientific and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Thermo Fisher Scientific's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Thermo Fisher Scientific's last four quarterly filings that the numbers alone won't show?”